AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.63
+8.97%Oct 6, 2026, 17:56 UTC
Avalo Therapeutics, Inc. reported that its phase 3 FURVENT trial of furmonertinib did not meet its primary progression-free-survival endpoint in previously untreated patients with EGFR exon 20 insertion non-small-cell lung cancer.
Source:Sep 23, 2026, 11:00 UTC
Avalo Therapeutics announced it will present late-breaker oral and poster data at the EADV Congress 2026 in Vienna, Austria, from September 30 to October 3, 2026.
Source:Aug 6, 2026, 11:00 UTC
Avalo Therapeutics announced its financial results for the second quarter of 2026.
Source:Jun 23, 2026, 00:00 UTC
Avalo Therapeutics appointed Ron Philip as a director, effective June 23, 2026.
Jun 16, 2026, 11:00 UTC
Avalo Therapeutics announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, for development in hidradenitis suppurativa and other inflammatory disorders.
Source: